New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing